Active Biotech postpone publication of the interim report
October 26 2016 - 2:27AM
Active Biotech has decided to postpone the publication of the
interim report for January-September 2016 to November 11, 2016,
after stock markets closing. Previously communicated date was
November 10, 2016.
Lund October 26, 2016
For further information, please contact Hans Kolam, CFO
Tel. +46 46 19 20 44
Active Biotech AB (publ) (Nasdaq Stockholm: ACTI) is a
biotechnology company with focus on neurodegenerative/inflammatory
diseases and cancer. Laquinimod, an orally administered small
molecule with unique immunomodulatory properties, is in pivotal
Phase 3 development for the treatment of relapsing remitting
multiple sclerosis. Also, laquinimod is in Phase 2 development for
the treatment of primary progressive multiple sclerosis and
Huntington's disease. Furthermore, commercial activities are
conducted for the tasquinimod, SILC, ANYARA and paquinimod
projects. Please visit www.activebiotech.com for more
information.
Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund, Sweden Tel: +46 (0)46 19 20 00
161026_new date_Q3
http://hugin.info/1002/R/2051112/767391.pdf
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Sep 2023 to Sep 2024